Home » EMA Releases Guideline on Trials of Drugs to Prevent Strokes, SEEs
EMA Releases Guideline on Trials of Drugs to Prevent Strokes, SEEs
September 10, 2012
Companies conducting clinical trials of drugs to prevent stroke and systemic embolic events (SEE) in patients with nonvalvular atrial fibrillation (AF) should use the composite primary efficacy endpoint of time from randomization to first stroke and SEEs, according to a European Medicines Agency (EMA) draft guideline.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor